Marqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of Marqibo (vinCRIStine sulfate LIPOSOME injection).

May 2, 2022 · The U.S. Food and Drug Administration (FDA) has withdrawn approval of MARQIBO (vincristine sulfate liposome injection) after a postmarking clinical trial failed to verify the clinical …

Marqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of Marqibo (vinCRIStine sulfate LIPOSOME injection).

Marqibo package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

Vincristine stabilizes the spindle apparatus by binding to tubulin, alters microtubule structure and function, and inhibits chromosome separation.

Feb 1, 2022 · Preferred therapies and recommendations are determined by review of clinical evidence. NCCN category of recommendation is taken into account as a component of this review. Regimens …

On August 9, 2012, the U. S. Food and Drug Administration granted accelerated approval for vinCRIStine sulfate LIPOSOME injection (Marqibo, Talon Therapeutics, Inc.) for the treatment of …

On May 2, 2022, the FDA withdrew approval of Marqibo after a postmarking clinical trial failed to verify the clinical benefit of the drug. The manufacturer voluntarily withdrew its new drug application and …

Based on findings in humans with non-liposomal vincristine sulfate and in animals administered vincristine sulfate liposome injection, Marqibo may impair fertility.

FDA-approved indication: Marqibo is a vinca alkaloid indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater …